Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adhesiveness of Rotigotine Patch in Parkinson's Disease
NCT06247410Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Countries
- 1
- Sponsor
- SocraTec R&D
- Modality
- Small Molecules
- Drugs
- rotigotine
- Conditions
- Parkinson's disease (PD)
01
Overview
Phase 2, randomised, open-label trial of rotigotine in Parkinson's disease (PD) (2 arms), sponsored by SocraTec R&D. Primary endpoint: Assessment of patch adhesion properties at 24 hours. Started Aug 2021; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Sequence: Reference-Test-Reference-Test
Reference (Neupro) -> Test (ROT-TDS) -> Reference -> Test
Sequence: Test-Reference-Test-Reference
Test (ROT-TDS) -> Reference (Neupro) -> Test -> Reference
03
Who it enrols
Patients with idiopathic Parkinson's disease on a stable dose of rotigotine (at least 8 mg/24 h) including use of an 8 mg/24 h patch.
04
Endpoints
Primary
Assessment of patch adhesion properties
Secondary
Skin tolerability of Test and Reference
Descriptive characterisation of safety and tolerability
Beyond the preview
Go deeper on NCT06247410.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247410.